CNM-Au8 Displays Evidence of Survival Benefit in Amyotrophic Lateral Sclerosis
Results from phase 2 RESCUE-ALS trial show that treatment with CNM-Au8 in ALS demonstrated improvement in survival compared to the estimated median survival rate.
Related Articles
Califf’s long day on Capitol Hill
Democrats and Republicans pressed FDA Commissioner Robert Califf on the FDA’s slow pace.
Enhanced Levels of Fractalkine and HSP60 in Cerebrospinal Fluid of Sporadic Amyotrophic Lateral Sclerosis Patients – PubMed
Amyotrophic Lateral Sclerosis (ALS) is a multifactorial neurodegenerative disorder with a significant contribution of non-cell autonomous mechanisms to motor neuronal degeneration. Amongst a plethora of…
Why an ALS Drug Was Pulled From the Market
Topline data show where sodium phenylbutyrate and taurursodiol fell short
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NEW YORK, April 16,…
BrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical Chief
By Ben Glickman BrainStorm Cell Therapeutics named a new medical chief and said Co-Chief Executive Stacy Lindborg would step down ahead of a long-awaited…
Certain Biotech Investors Get an Early Look at Results. Is That Fair?
Private investments in public equities, or PIPEs, are all the rage in biotech, but some investors resent the sharing of nonpublic information.
Every 90, 85, 80, 75 Minutes
“Every 90 Minutes” has been a tagline that organizations have used for over a decade to describe how often someone dies from ALS in the…
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory…
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the…
Americans Are Spending Billions on Drugs That Don’t Work
Companies are increasingly using fast-track approval processes to get unproven treatments to patients.